MX2016004580A - Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. - Google Patents
Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.Info
- Publication number
- MX2016004580A MX2016004580A MX2016004580A MX2016004580A MX2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A MX 2016004580 A MX2016004580 A MX 2016004580A
- Authority
- MX
- Mexico
- Prior art keywords
- pcsk9 inhibitor
- treat hyperlipidemia
- pcsk9
- present
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Abstract
La presente invención proporciona métodos para tratar la hiperlipidemia en pacientes que no están recibiendo una terapia de estatinas. Los métodos de la presente invención comprenden administrar a un paciente una composición farmacéutica que comprende un inhibidor de PCSK9. En determinadas realizaciones, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9 tal como el anticuerpo ilustrativo denominado en la presente memoria mAb316P.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890154P | 2013-10-11 | 2013-10-11 | |
US201461923103P | 2014-01-02 | 2014-01-02 | |
US201461955514P | 2014-03-19 | 2014-03-19 | |
US201462004620P | 2014-05-29 | 2014-05-29 | |
US201462025104P | 2014-07-16 | 2014-07-16 | |
EP14306221 | 2014-07-31 | ||
US201462054571P | 2014-09-24 | 2014-09-24 | |
EP14306584 | 2014-10-09 | ||
PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004580A true MX2016004580A (es) | 2016-12-08 |
Family
ID=52813751
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004580A MX2016004580A (es) | 2013-10-11 | 2014-10-10 | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
MX2022013172A MX2022013172A (es) | 2013-10-11 | 2016-04-08 | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
MX2020004023A MX2020004023A (es) | 2013-10-11 | 2016-04-08 | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013172A MX2022013172A (es) | 2013-10-11 | 2016-04-08 | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
MX2020004023A MX2020004023A (es) | 2013-10-11 | 2016-04-08 | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20150140002A1 (es) |
EP (2) | EP3689913B1 (es) |
JP (2) | JP6846931B2 (es) |
KR (3) | KR20220048051A (es) |
CN (3) | CN115192704A (es) |
AU (2) | AU2014331754B2 (es) |
CA (1) | CA2926942A1 (es) |
EA (1) | EA037526B1 (es) |
ES (1) | ES2914978T3 (es) |
IL (1) | IL244995B (es) |
MX (3) | MX2016004580A (es) |
PL (2) | PL3055333T4 (es) |
TW (1) | TWI669131B (es) |
WO (1) | WO2015054619A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
CA2825838C (en) | 2011-01-28 | 2020-10-27 | Sanofi | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
WO2016010927A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
EP3169353B1 (en) | 2014-07-16 | 2019-12-18 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
US20180140747A1 (en) * | 2015-04-15 | 2018-05-24 | ConcieValve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
KR20180034672A (ko) * | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-pcsk9 항체 |
WO2018189705A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
US20200131576A1 (en) | 2017-04-25 | 2020-04-30 | The Brigham And Women's Hospital, Inc. | IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis |
CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
WO2018228406A1 (zh) * | 2017-06-14 | 2018-12-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
TW201945401A (zh) * | 2018-03-06 | 2019-12-01 | 法商賽諾菲生物技術公司 | 降低心血管風險的方法 |
MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
US20230312750A1 (en) * | 2019-11-18 | 2023-10-05 | Ad Pharmaceuticals Co., Ltd. | Anti-pcsk9 antibody and use thereof |
KR20220125249A (ko) * | 2019-12-10 | 2022-09-14 | 리제너론 파아마슈티컬스, 인크. | 동형접합 가족성 고콜레스테롤혈증을 치료하기 위한 pcsk9 억제제의 용도 |
CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
CA2825838C (en) * | 2011-01-28 | 2020-10-27 | Sanofi | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
ES2773111T3 (es) * | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Application Discontinuation
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Application Discontinuation
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en active Application Filing
- 2014-10-10 MX MX2016004580A patent/MX2016004580A/es active IP Right Grant
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active IP Right Cessation
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
PH12016502355A1 (en) | Pharmaceutical composition | |
PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
IN2015DN00450A (es) | ||
PH12016502352A1 (en) | Pharmaceutical composition | |
PH12016502353A1 (en) | Pharmaceutical composition | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2018011607A (es) | Sultiame para el tratamiento de apnea del sueño. | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина | |
EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы | |
UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |